GUARDANT HEALTH INC (GH) Stock News

Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 30.2% year on year to $201.8 million. Its GAAP loss of $0.90 per share was 12.4% below analysts’ consensus estimates.

Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 30.2% year on year to $201.8 million. Its GAAP loss of $0.90 per share was 12.4% below analysts’ consensus estimates.

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Stock Sees RS Rating Jump To 83

On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83.

Mentions: HIMS CSTL DGX

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.

Mentions: EXAS

Guardant Health Tops Q4 Revenue Forecast

The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses.

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

Guardant Health to Participate in Upcoming Investor Conferences

Why Guardant Health Stock Blasted 13% Higher on Thursday

Earnings Scheduled For February 20, 2025

Mentions: CELH NEXA DNB PRTA ...

Guardant Health Announces Debt Exchange Transactions

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

/PRNewswire/ -- USA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January...

Mentions: ONCY AGEN XLO RNXT ...

Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone

The company is working to expand the uses and reimbursement for its blood-based tests for cancer.

Mentions: EXAS NTRA

Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients

Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results

Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer

Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Sheffield United Is Latest Football Club to Agree US Takeover

An American consortium has agreed to buy Sheffield United, one of the biggest English football teams outside the Premier League.

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™

/PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today announced that a jury in the U.S. District...

Mentions: NTRA

Deciphering Disruption: Inside Cathie Wood's Latest Plays

Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies.

Mentions: AMZN PACB TTD COIN ...

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)